Last reviewed · How we verify
NCT05697120
Long-term Effects of Individualized Follow-up With an App for One Year
trial in Coronary Artery Disease in 102 participants. Completed in 7 September 2023.
7 September 2023
Quick facts
| Lead sponsor | Oslo Metropolitan University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 102 |
| Start date | 7 February 2023 |
| Primary completion | 7 September 2023 |
| Estimated completion | 7 September 2023 |
| Sites | 1 location across Norway |
Conditions studied
- Coronary Artery Disease — all drugs for Coronary Artery Disease →
Sponsor
Oslo Metropolitan University
Who can join
41 and older, any sex, with Coronary Artery Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to examine the long-term (3-5 year post intervention) effects post individualized follow-up with an app for one year, compared to a control group that received usual care on factors related to healthy behaviour in patients post-CR.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Effects of Individualized Follow-Up With an App Postcardiac Rehabilitation: Five-Year Follow-Up of a Randomized Controlled Trial.
Lunde P, Bye A, Grimsmo J, Pripp AH, et al · · 2025 · cited 6× · PMID 39946716 · DOI 10.2196/60256 -
Effect of a mHealth intervention on health literacy in patients completing cardiac rehabilitation: A randomized controlled trial with one- and five-year follow-up.
Lunde P, Finbråten HS, Pripp AH, Nilsson BB, et al · · 2025 · cited 3× · PMID 40534777 · DOI 10.1016/j.ijcrp.2025.200445
Verify or expand the search:
- PubMed search for NCT05697120
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Coronary Artery Disease
Currently open trials in the same condition.
- NCT07399002 — LONG NAGOMI™ PMCF STUDY · recruiting
- NCT07420582 — Antegrade Autologous Blood Reinfusion After CPB · recruiting
- NCT07493603 — A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease · Phase 1, PHASE2 · recruiting
- NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
- NCT07286578 — A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Under · NA · recruiting
Other Oslo Metropolitan University trials
Trials by the same sponsor.
- NCT06578260 — Support Groups - a Model for Social Inclusion and Reduction of Bullying in School · NA · recruiting
- NCT05784324 — COMPRESSED - A Longitudinal Study of Compressed Work Schedules Within the Health, Care and Welfare Services · not yet recruiting
- NCT05895604 — The Mother in Norway Study · NA · recruiting
- NCT06117098 — Mobile App for Risk Reduction of Type 2 Diabetes · NA · unknown
- NCT05919355 — Effectiveness of a Communication Device in Home Care Services in Norway: Does Komp Make Older Adults Feel Happier, Safer · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05697120 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Oslo Metropolitan University
- Last refreshed: 11 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05697120.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing